1. Home
  2. MREO vs ALT Comparison

MREO vs ALT Comparison

Compare MREO & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • ALT
  • Stock Information
  • Founded
  • MREO 2015
  • ALT 1997
  • Country
  • MREO United Kingdom
  • ALT United States
  • Employees
  • MREO N/A
  • ALT N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • MREO Health Care
  • ALT Health Care
  • Exchange
  • MREO Nasdaq
  • ALT Nasdaq
  • Market Cap
  • MREO 482.5M
  • ALT 472.3M
  • IPO Year
  • MREO N/A
  • ALT N/A
  • Fundamental
  • Price
  • MREO $2.50
  • ALT $5.20
  • Analyst Decision
  • MREO Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • MREO 6
  • ALT 8
  • Target Price
  • MREO $7.83
  • ALT $20.83
  • AVG Volume (30 Days)
  • MREO 1.5M
  • ALT 2.6M
  • Earning Date
  • MREO 03-26-2025
  • ALT 05-08-2025
  • Dividend Yield
  • MREO N/A
  • ALT N/A
  • EPS Growth
  • MREO N/A
  • ALT N/A
  • EPS
  • MREO N/A
  • ALT N/A
  • Revenue
  • MREO $1,000,000.00
  • ALT $20,000.00
  • Revenue This Year
  • MREO N/A
  • ALT N/A
  • Revenue Next Year
  • MREO N/A
  • ALT N/A
  • P/E Ratio
  • MREO N/A
  • ALT N/A
  • Revenue Growth
  • MREO N/A
  • ALT N/A
  • 52 Week Low
  • MREO $2.25
  • ALT $5.14
  • 52 Week High
  • MREO $5.02
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • MREO 38.26
  • ALT 33.93
  • Support Level
  • MREO $2.39
  • ALT $5.15
  • Resistance Level
  • MREO $2.59
  • ALT $6.09
  • Average True Range (ATR)
  • MREO 0.17
  • ALT 0.42
  • MACD
  • MREO 0.02
  • ALT -0.06
  • Stochastic Oscillator
  • MREO 39.87
  • ALT 3.66

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Share on Social Networks: